Conversely, the cutoff for IHC staining was a strong CLDN18.2 expression (IHC 2+/3+ in ≥75% of tumor cells) in two recent phase III trials (SPOTLIGHT and GLOW) [8,9]. This evidence concerns the gene CLDN18 and neoplasm.